Adverse Effects of Medical Cannabinoids a Systematic Review

Review

. 2008 Jun 17;178(13):1669-78.

doi: x.1503/cmaj.071178.

Agin furnishings of medical cannabinoids: a systematic review

Affiliations

• PMID: 18559804
• PMCID: PMC2413308
• DOI: 10.1503/cmaj.071178

Complimentary PMC article

Review

Adverse effects of medical cannabinoids: a systematic review

Tongtong Wang  et al. CMAJ. 2008 .

Costless PMC commodity

Abstruse

Groundwork: The therapeutic use of cannabis and cannabis-based medicines raises safe concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most rubber information comes from studies of recreational use.

Methods: We performed a systematic review of rubber studies of medical cannabinoids published over the past 40 years to create an bear witness base of operations for cannabis-related adverse events and to facilitate time to come cannabis research initiatives. We critically evaluated the quality of published studies with a view to identifying ways to meliorate future studies.

Results: A total of 321 manufactures were eligible for evaluation. After excluding those that focused on recreational cannabis utilise, we included 31 studies (23 randomized controlled trials and 8 observational studies) of medical cannabis employ in our analysis. In the 23 randomized controlled trials, the median duration of cannabinoid exposure was 2 weeks (range viii hours to 12 months). A full of 4779 adverse events were reported among participants assigned to the intervention. Most (4615 [96.6%]) were not serious. Of the 164 serious adverse events, the nigh common was relapse of multiple sclerosis (21 events [12.8%]), vomiting (16 events [9.viii%]) and urinary tract infection (15 events [ix.i%]). The charge per unit of nonserious adverse events was higher amongst participants assigned to medical cannabinoids than among controls (rate ratio [RR] 1.86, 95% confidence interval [CI] one.57-2.21); the rates of serious agin events did not differ significantly between these ii groups (RR 1.04, 95% CI 0.78-one.39). Dizziness was the most commonly reported nonserious agin event (714 events [15.v%]) among people exposed to cannabinoids.

Interpretation: Brusk-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events. The risks associated with long-term use were poorly characterized in published clinical trials and observational studies. High-quality trials of long-term exposure are required to further narrate condom issues related to the use of medical cannabinoids.

Figures

Figure 1: Retrieval and selection of studies of safe of cannabinoid preparations.

Figure two: Incidence rates and rate ratios (random-furnishings model) for nonserious adverse events among participants assigned to medical cannabinoid therapy or control in 23 randomized controlled trials. Dotted vertical line represents no difference between the intervention and the control. CI = confidence interval.

Like manufactures

• Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

  Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Smith LA, et al. Cochrane Database Syst Rev. 2015 Nov 12;2015(xi):CD009464. doi: 10.1002/14651858.CD009464.pub2. Cochrane Database Syst Rev. 2015. PMID: 26561338 Free PMC commodity. Review.

• Cannabis for the treatment of ulcerative colitis.

  Kafil TS, Nguyen TM, MacDonald JK, Chande N. Kafil TS, et al. Cochrane Database Syst Rev. 2018 Nov 8;xi(xi):CD012954. doi: 10.1002/14651858.CD012954.pub2. Cochrane Database Syst Rev. 2018. PMID: 30406638 Complimentary PMC commodity.

• [Cannabinoids in palliative intendance: Systematic review and meta-analysis of efficacy, tolerability and rubber].

  Mücke Grand, Carter C, Cuhls H, Prüß K, Radbruch L, Häuser W. Mücke Thousand, et al. Schmerz. 2016 Feb;30(1):25-36. doi: 10.1007/s00482-015-0085-2. Schmerz. 2016. PMID: 26809975 Review. German.

• Suicidal Ideation.

  Harmer B, Lee Southward, Duong TVH, Saadabadi A. Harmer B, et al. 2021 Aug half dozen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 January–. 2021 Aug half dozen. In: StatPearls [Cyberspace]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 33351435 Free Books & Documents.

• [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].

  Petzke F, Enax-Krumova EK, Häuser West. Petzke F, et al. Schmerz. 2016 Feb;thirty(1):62-88. doi: 10.1007/s00482-015-0089-y. Schmerz. 2016. PMID: 26830780 Review. German.

Cited by 95 articles

• The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies.

  Prakash Due south, Carter WG. Prakash Southward, et al. Brain Sci. 2021 Nov 28;11(12):1573. doi: ten.3390/brainsci11121573. Brain Sci. 2021. PMID: 34942876 Complimentary PMC article. Review.

• Inflammaging and Cannabinoids.

  Baban B, Khodadadi H, Salles ÉL, Costigliola V, Morgan JC, Hess DC, Vaibhav K, Dhandapani KM, Yu JC. Baban B, et al. Ageing Res Rev. 2021 Dec;72:101487. doi: 10.1016/j.arr.2021.101487. Epub 2021 Oct 15. Ageing Res Rev. 2021. PMID: 34662745 Review.

• Cannabinoids for the handling of dementia.

  Bosnjak Kuharic D, Markovic D, Brkovic T, Jeric Kegalj M, Rubic Z, Vuica Vukasovic A, Jeroncic A, Puljak L. Bosnjak Kuharic D, et al. Cochrane Database Syst Rev. 2021 Sep 17;9(9):CD012820. doi: 10.1002/14651858.CD012820.pub2. Cochrane Database Syst Rev. 2021. PMID: 34532852 Review.

• Cannabis and Autoimmunity: Possible Mechanisms of Activity.

  Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni South, Sarzi-Puttini P. Giorgi V, et al. Immunotargets Ther. 2021 Jul 21;10:261-271. doi: 10.2147/ITT.S267905. eCollection 2021. Immunotargets Ther. 2021. PMID: 34322454 Free PMC article. Review.

• Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.

  Pisani S, McGoohan M, Velayudhan L, Bhattacharyya S. Pisani Southward, et al. Drugs Aging. 2021 Oct;38(10):887-910. doi: 10.1007/s40266-021-00882-2. Epub 2021 Jul 8. Drugs Crumbling. 2021. PMID: 34235645

Publication types

MeSH terms

Substances

LinkOut - more than resource

• Total Text Sources

  • ClinicalKey
  • Europe PubMed Key
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Key

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • ClinicalTrials.gov
  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal

brockloverrien.blogspot.com

Source: https://pubmed.ncbi.nlm.nih.gov/18559804/

Share this post